Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 7:54 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2257–2280 of 3,473 matching trials from the live ClinicalTrials.gov search.
Conditions
HER2-positive Breast Cancer
Interventions
HER-2 pulsed DC1, Trastuzumab, Pertuzumab, Paclitaxel, Resection surgery
Biological · Drug · Procedure
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Tampa, Florida
Withdrawn Not applicable Interventional Accepts healthy volunteers

Blood Neurotrophic Factors in Adults

NCT00505349
Conditions
Healthy
Interventions
Computer-based cognitive training
Behavioral
Lead sponsor
Posit Science Corporation
Industry
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
San Francisco, California
Conditions
Rotator Cuff Tear
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 75 Years
Enrollment
495 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Prostate Cancer, Renal Cancer, Urethral Cancer, Advanced Solid Tumor, Metastatic Castration-resistant Prostate Cancer, Solid Tumor, Adult
Interventions
Copper-64 labeled Granzyme B (64Cu-GRIP B), Positron Emission Tomography (PET)
Drug · Procedure
Lead sponsor
Rahul Aggarwal
Other
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
San Francisco, California
Conditions
Atypical Ductal Breast Hyperplasia, Atypical Lobular Breast Hyperplasia, BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, Ductal Breast Carcinoma in Situ, Lobular Breast Carcinoma in Situ
Interventions
counseling intervention, behavioral dietary intervention, exercise intervention, questionnaire administration, laboratory biomarker analysis
Other · Behavioral
Lead sponsor
University of Washington
Other
Eligibility
35 Years to 65 Years · Female only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Non-small Cell Lung Cancer, Postmenopausal Women
Interventions
fulvestrant (Faslodex), anastrozole (Arimidex), Bevacizumab (Avastin), Best supportive care
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Completed No phase listed Observational

Dynamic Cardiac SPECT Imaging

NCT01934985
Conditions
Coronary Artery Disease
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
21 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
1
States / cities
San Francisco, California
Conditions
Metastatic Melanoma
Interventions
Ipilimumab, Stereotactic Body Radiation Therapy
Drug · Radiation
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Stage I Non-Small Cell Lung Cancer AJCC v7, Stage IA Non-Small Cell Lung Carcinoma AJCC v7, Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7
Interventions
Laboratory Biomarker Analysis, Quality-of-Life Assessment, Stereotactic Body Radiation Therapy, Thoracic Surgical Procedure
Other · Drug · Procedure
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Buffalo, New York
Conditions
Recurrent Melanoma, Stage IV Melanoma
Interventions
cyclophosphamide, aldesleukin, autologous tumor cell vaccine, laboratory biomarker analysis, immunologic technique, immunohistochemistry staining method, polymerase chain reaction, therapeutic autologous lymphocytes
Drug · Biological · Other + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Prostate Carcinoma
Interventions
Best Practice, Discussion, Survey Administration, Virtual Reality
Other · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
Male only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Jacksonville, Florida
Conditions
Cigarette Smoking-Related Carcinoma
Interventions
Smartphone App-delivered Smoking Cessation Intervention, Health Promotion and Education, Biospecimen Collection, Questionnaire Administration
Behavioral · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 30 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Seattle, Washington
Conditions
High-risk Smoldering Multiple Myeloma, Smoldering Multiple Myeloma, Multiple Myeloma
Interventions
Teclistamab, Lenalidomide, Dexamethasone
Drug
Lead sponsor
Irene Ghobrial, MD
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
3
States / cities
Denver, Colorado • Boston, Massachusetts • Portland, Oregon
Conditions
Locally Advanced Urothelial Carcinoma, Oligo-metastaic Urothelial Carcinoma
Interventions
Radical cystectomy
Procedure
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
2
States / cities
New Haven, Connecticut • Madison, Wisconsin
Conditions
Colon Cancer
Interventions
Bevacizumab, Cetuximab, 5-fluorouracil, Leucovorin, Oxaliplatin
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
10
States / cities
Evansville, Indiana • Louisville, Kentucky • Portland, Maine + 7 more
Conditions
Hematopoietic and Lymphoid System Neoplasm, Malignant Solid Neoplasm
Interventions
Best Practice, Comprehensive Geriatric Assessment, Electronic Health Record Review, Questionnaire Administration, Supportive Care, Telemedicine
Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
65 Years and older
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
3
States / cities
Duarte, California • Lancaster, California • Upland, California
Conditions
Type II and IIa Open Tibia Fractures
Interventions
delayed closure, immediate wound closure
Procedure
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
15 Years and older
Enrollment
451 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Charlotte, North Carolina
Conditions
Childhood Langerhans Cell Histiocytosis, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
umbilical cord blood transplantation
Procedure
Lead sponsor
Herbert Irving Comprehensive Cancer Center
Other
Eligibility
Up to 60 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
1
States / cities
New York, New York
Conditions
Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Computed Tomography, Echocardiography Test, Multigated Acquisition Scan, Olaparib, Selumetinib Sulfate
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
292
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 229 more
Conditions
Breast Cancer, Fertility, Contraception, Menopausal Symptoms
Interventions
Multi-component oncofertility care intervention
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
4
States / cities
Brawley, California • El Centro, California • La Jolla, California
Conditions
Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IIX (Bulky) Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation, Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Grade 3b Follicular Lymphoma, HHV8-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, High Grade B-Cell Lymphoma, Not Otherwise Specified, Intravascular Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma, Nodular Lymphocyte Predominant B-Cell Lymphoma, Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions
Biospecimen Collection, Computed Tomography, Cyclophosphamide, Doxorubicin Hydrochloride, Echocardiography Test, Multigated Acquisition Scan, Oral Azacitidine, Positron Emission Tomography, Prednisone, Questionnaire Administration, Rituximab, Rituximab and Hyaluronidase Human, Vincristine Sulfate
Procedure · Drug · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
75 Years and older
Enrollment
422 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
176
States / cities
Tucson, Arizona • Little Rock, Arkansas • Anaheim, California + 136 more
Conditions
Metastatic Clear Cell Renal Cell Carcinoma
Interventions
Hydroxychloroquine, RAD001
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
3
States / cities
New Brunswick, New Jersey • Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania
Conditions
Brain Tumors, Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Head and Neck Cancer, Lymphoma, Nausea, Vomiting, Neuroblastoma, Ovarian Cancer, Sarcoma
Interventions
electroacupuncture therapy, sham intervention, quality-of-life assessment
Procedure
Lead sponsor
Children's Oncology Group
Network
Eligibility
5 Years to 35 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Grade I Meningioma, Adult, Grade II Meningioma, Adult, Grade III Meningioma, Adult, Recurrent Meningioma
Interventions
Pembrolizumab, Stereotactic Radiosurgery
Drug · Procedure
Lead sponsor
Nancy Ann Oberheim Bush, MD
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
1
States / cities
San Francisco, California